Condition

Pancreatic Ductal Adenocarcinoma (PDAC)

ClinicalTrials.gov condition label

Clinical trials20

Recruiting12

Common interventions25

Lead sponsors shown15

Clinical trials

20 shown

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · 2026-06-30

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsNCT07410494 · 2026-02-01

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT07435038 · 2026-01-29

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047 · 2025-11-25

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07

A Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · 2025-04-18

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT06895031 · 2025-03-31

KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410 · 2023-10-18

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541 · 2023-09-07

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsNCT05706129 · 2023-03-14

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985 · 2022-05-31

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid TumorsNCT07624214 · 2026-07-01

NOT_YET_RECRUITING

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)NCT06710132 · 2025-01-29

ACTIVE_NOT_RECRUITING

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D MutationNCT06599502 · 2024-10-18

"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational StudyNCT06044064 · 2023-12-01

NOT_YET_RECRUITING

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid TumoursNCT05605522 · 2023-02-07

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsNCT04083599 · 2019-09-17

ACTIVE_NOT_RECRUITING

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsNCT03811652 · 2018-12-20

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NCT03549000 · 2018-07-18

Common interventions

Leading sponsors

Revolution Medicines, Inc.3 3B Pharmaceuticals GmbH1 Asian Institute of Gastroenterology, India1 AstraZeneca1 Betta Pharmaceuticals Co., Ltd.1 Blue Earth Diagnostics1 Bristol-Myers Squibb1 EMD Serono Research & Development Institute, Inc.1 Essen Biotech1 Genmab1 Guangzhou JOYO Pharma Co., Ltd1 Kura Oncology, Inc.1 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.1 Lumara Bio Oncologics GmbH1 MedImmune LLC1

Trial status mix

RECRUITING12

TERMINATED3

ACTIVE_NOT_RECRUITING2

NOT_YET_RECRUITING2

COMPLETED1

Phase mix

PHASE117

PHASE210

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.